KR20180095647A - 신장결석 치료용 약학적 제제 및 이의 제조방법 및 이용방법 - Google Patents

신장결석 치료용 약학적 제제 및 이의 제조방법 및 이용방법 Download PDF

Info

Publication number
KR20180095647A
KR20180095647A KR1020187020408A KR20187020408A KR20180095647A KR 20180095647 A KR20180095647 A KR 20180095647A KR 1020187020408 A KR1020187020408 A KR 1020187020408A KR 20187020408 A KR20187020408 A KR 20187020408A KR 20180095647 A KR20180095647 A KR 20180095647A
Authority
KR
South Korea
Prior art keywords
composition
component
disease
reducing agent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187020408A
Other languages
English (en)
Korean (ko)
Inventor
데니스 엘리아스 사데
조셉 비터맨
Original Assignee
임프리미스 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임프리미스 파마슈티컬스 인코포레이티드 filed Critical 임프리미스 파마슈티컬스 인코포레이티드
Publication of KR20180095647A publication Critical patent/KR20180095647A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187020408A 2015-12-22 2016-12-19 신장결석 치료용 약학적 제제 및 이의 제조방법 및 이용방법 Withdrawn KR20180095647A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562271020P 2015-12-22 2015-12-22
US62/271,020 2015-12-22
US201562272894P 2015-12-30 2015-12-30
US62/272,894 2015-12-30
PCT/US2016/067466 WO2017112574A1 (en) 2015-12-22 2016-12-19 Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof

Publications (1)

Publication Number Publication Date
KR20180095647A true KR20180095647A (ko) 2018-08-27

Family

ID=59064032

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020408A Withdrawn KR20180095647A (ko) 2015-12-22 2016-12-19 신장결석 치료용 약학적 제제 및 이의 제조방법 및 이용방법

Country Status (7)

Country Link
US (1) US20170172960A1 (enExample)
EP (1) EP3393469A4 (enExample)
JP (1) JP2019504024A (enExample)
KR (1) KR20180095647A (enExample)
AU (1) AU2016378399A1 (enExample)
CA (1) CA3009332A1 (enExample)
WO (1) WO2017112574A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472160B2 (en) * 2017-06-16 2025-11-18 Altibio, Inc. Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
US20190282525A1 (en) * 2018-03-19 2019-09-19 Cronus Research Labs Private Limited Tiopronin oral composition
WO2020092402A1 (en) * 2018-10-30 2020-05-07 Harrow Health, Inc. Pharmaceutical compositions of tiopronin and methods for preparing thereof
WO2022015743A1 (en) * 2020-07-14 2022-01-20 GyanRx Sciences, Inc. Methods of treating kidney stones
WO2022250957A2 (en) * 2021-05-10 2022-12-01 Altibio, Inc. Thioester prodrugs for the treatment of renal anomalies
BE1033278B1 (fr) * 2024-12-31 2026-08-12 Renal Care & Res Composition anti-lithiase
BE1033276B1 (fr) * 2024-12-31 2026-08-12 Renal Care & Res Composition anti-lithiase
WO2026146126A1 (fr) 2024-12-31 2026-07-09 Renal Care & Research Composition anti-lithiase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025839A1 (en) * 2003-07-28 2005-02-03 Polli James Edward Formulation approach to enhance transporter-mediated drug uptake
CN100361653C (zh) * 2004-09-29 2008-01-16 上海华源医药科技发展有限公司 硫普罗宁软胶囊
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
CN1833637A (zh) * 2005-03-16 2006-09-20 安徽龙科马生物制药有限责任公司 一种新的硫普罗宁冻干粉制剂及其制备方法
CN1698594A (zh) * 2005-04-25 2005-11-23 中国药科大学 硫普罗宁的缓释制剂
CN101062024B (zh) * 2006-04-25 2012-11-07 刘祥华 一种硫普罗宁组合药物及其制备方法
FR2967578B1 (fr) * 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
US8916609B2 (en) * 2011-06-10 2014-12-23 New York University Compounds as L-cystine crystallization inhibitors and uses thereof
CN102516143B (zh) * 2012-01-06 2013-11-20 刘全胜 一种硫普罗宁无菌粉及其制剂与制备方法
WO2014145195A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent

Also Published As

Publication number Publication date
CA3009332A1 (en) 2017-06-29
US20170172960A1 (en) 2017-06-22
WO2017112574A1 (en) 2017-06-29
EP3393469A4 (en) 2019-09-25
AU2016378399A1 (en) 2018-06-28
JP2019504024A (ja) 2019-02-14
EP3393469A1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
US20170172960A1 (en) Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof
Ballatori et al. N-acetylcysteine as an antidote in methylmercury poisoning
CN1165483B (zh) 顺氯氨铂和2,2'-二硫代-二(乙磺酸盐)(二巯乙磺酸钠)的组合物
RU2392926C2 (ru) Оральная композиция для абсорбции фосфорных соединений
FI87528B (fi) Foerfarande foer framstaellning av en oral dosenhet av kaliumklorid
RU2002106748A (ru) Фармацевтические соли трамадола
CN101528218A (zh) 治疗粘膜炎的组合物和方法
US20090075950A1 (en) Dosage Forms Containing A PPI, NSAID And A Buffer
JPS5857315A (ja) 製薬学的調製物
WO2011008976A1 (en) N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen
DE102014008685A1 (de) Freisetzungssystem für therapeutisches Gas
ES2946237T3 (es) Sistemas de dos componentes que comprenden ácido acetilsalicílico y una sal de carbonato
HUE032753T2 (en) A pharmaceutical composition comprising a hydrogen carbonate salt and its use as a medicament for the treatment and / or prevention of urinary and related diseases
AU2020204558A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof
ES2946260T3 (es) Sistemas de dos componentes que comprenden ácido acetilsalicílico y una sal de fosfato
RU2354378C1 (ru) Комбинированный противотуберкулезный препарат
DK166343B (da) Forbedret piroxicamholdigt laegemiddel
KR100367877B1 (ko) 구연산칼륨을 주제로 한 요로결석 치료제중 분말 및 미립제형 의 제조방법
RU2247560C1 (ru) Комбинированный состав с противотуберкулёзным действием
RU2247559C1 (ru) Противотуберкулёзное средство
KR101308142B1 (ko) 상황버섯 균사체 추출물을 유효성분으로 함유하는 면역 억제용 조성물
EP3870175A1 (en) Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
JPWO2019059172A1 (ja) 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用
RU2174836C1 (ru) Фармацевтическая композиция, обладающая анальгезирующим действием
KR102619489B1 (ko) 폴마콕시브 및 트라마돌을 포함하는 급, 만성 통증 치료용 약제학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000